Ann Kristin Kvam1, Peter M Fayers, Finn Wisloff. 1. Department of Haematology, Oslo University Hospital, Ullevaal Faculty of Medicine, University of Oslo, Oslo, Norway. a.k.kvam@medisin.uio.no
Abstract
OBJECTIVES: The aims of this study were to (i) compare the responsiveness of the EORTC QLQ-C30 cancer-specific questionnaire and the generic questionnaires EQ-5D and 15D used for economic evaluation of healthcare interventions and (ii) determine the minimal important differences (MIDs) in these questionnaires. The MID is the smallest change in a quality-of-life score considered important to patients. METHODS: Between 2006 and 2008, 239 patients with multiple myeloma completed the questionnaires at inclusion (T1) and after 3 months (T2). At T2, patients were asked whether they had noticed any change in their quality of life. Responsiveness and MIDs were determined by mean score changes (T2-T1) for patients who, in the interview, stated they had improved, deteriorated, or were unchanged. Responsiveness was also assessed using standardized response means. Wilcoxon tests for pair differences were used to evaluate the statistical significance of the changes. RESULTS: Patients who improved had significantly (P < 0.01) higher scores at T2 in all three questionnaires. Patients who deteriorated reported lower scores at T2; however, for the 15D, the differences in score were not statistically significant. The MIDs for the QLQ-C30, EQ-5D, and 15D were 8, 0.08, and 0.03 in patients who improved and 12, 0.10 and 0.02 in patients who deteriorated, respectively. CONCLUSIONS: All three questionnaires showed an acceptable responsiveness in patients who improved. However, the 15D did not respond optimally in patients who deteriorate and cannot be recommended for use in patients with myeloma.
OBJECTIVES: The aims of this study were to (i) compare the responsiveness of the EORTC QLQ-C30 cancer-specific questionnaire and the generic questionnaires EQ-5D and 15D used for economic evaluation of healthcare interventions and (ii) determine the minimal important differences (MIDs) in these questionnaires. The MID is the smallest change in a quality-of-life score considered important to patients. METHODS: Between 2006 and 2008, 239 patients with multiple myeloma completed the questionnaires at inclusion (T1) and after 3 months (T2). At T2, patients were asked whether they had noticed any change in their quality of life. Responsiveness and MIDs were determined by mean score changes (T2-T1) for patients who, in the interview, stated they had improved, deteriorated, or were unchanged. Responsiveness was also assessed using standardized response means. Wilcoxon tests for pair differences were used to evaluate the statistical significance of the changes. RESULTS:Patients who improved had significantly (P < 0.01) higher scores at T2 in all three questionnaires. Patients who deteriorated reported lower scores at T2; however, for the 15D, the differences in score were not statistically significant. The MIDs for the QLQ-C30, EQ-5D, and 15D were 8, 0.08, and 0.03 in patients who improved and 12, 0.10 and 0.02 in patients who deteriorated, respectively. CONCLUSIONS: All three questionnaires showed an acceptable responsiveness in patients who improved. However, the 15D did not respond optimally in patients who deteriorate and cannot be recommended for use in patients with myeloma.
Authors: Kevin W Song; Meletios A Dimopoulos; Katja C Weisel; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Mara S Monzini; Mohamed Zaki; Christian Jacques; Jesus San Miguel Journal: Haematologica Date: 2014-11-25 Impact factor: 9.941
Authors: Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941
Authors: A Keith Stewart; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Jacqui Buchanan; Kim Cocks; Xinqun Yang; Biao Xing; Naseem Zojwalla; Margaret Tonda; Philippe Moreau; Antonio Palumbo Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: Deborah Y Park; Martin C Tom; Wei Wei; Surabhi Tewari; Manmeet S Ahluwalia; Jennifer S Yu; Samuel T Chao; John H Suh; David Peereboom; Glen H J Stevens; Gene H Barnett; Lilyana Angelov; Alireza M Mohammadi; Thomas Hogan; Courtney Kissel; Brittany Lapin; Isabel Schuermeyer; Michael W Parsons; Richard Naugle; Erin S Murphy Journal: J Neurooncol Date: 2022-01-22 Impact factor: 4.130
Authors: Stefan Knop; Maria-Victoria Mateos; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ganna Usenko; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Losava; Tomoaki Fujisaki; Mamta Garg; Jianping Wang; Susan Wroblewski; Anupa Kudva; Katharine S Gries; John Fastenau; Jesus San-Miguel; Michele Cavo Journal: BMC Cancer Date: 2021-06-02 Impact factor: 4.430